Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined Using Multiple Serological Assay Formats

Nesbitt, D; Jin, Daniel; Hogan, Joseph W.; Chan, Philip A.; Simon, Melissa J.; Vargas, Matthew; King, Ewa; Huard, Richard C.; Bandy, Utpala; Hillyer, Christopher D.; Luchsinger, Larry L.

doi:10.21203/rs.3.rs-76664/v1

Cited by 5 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings were also in line with previous studies, which showed that early in the pandemic the seroprevalence of COVID-19 in blood donors or other nontargeted populations was very low, ranging from 0% to 2.0% (Erikstrup et al, 2021;Godbout et al, 2020;Qutob et al, 2021;Xu et al, 2020;Ho et al, 2020;Banjar et al, 2021;Nesbitt et al, 2021;Slot et al, 2020;Fiore et al, 2021;Saeed et al, 2021). However, other studies, especially those from hard-hit communities early in the pandemic, showed relatively high rates of up to 23% (Rosenberg et al, 2020;Percivalle et al, 2020).…”

Section: Discussionsupporting

confidence: 92%

“…These population-based seroprevalence studies varied in the targeted populations tested and in the recruitment strategies used, which may explain some of the variation. Among the populations tested were healthy blood donors (Amorim Filho et al, 2020;Sughayer et al, 2020;Slot et al, 2020;Nesbitt et al, 2021;Gallian et al, 2020;Olariu et al, 2021;Younas et al, 2020;Banjar et al, 2021;Uyoga et al, 2021;Busch and Stone, 2021;Martinez-Acuña et al, 2020;Saeed et al, 2021;Fiore et al, 2021). Again, the seroprevalence among healthy blood donors and other population groups studied varied according to the community tested and the time of testing, in terms of the pandemic evolution (Lai et al, 2020;Rostami et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic

Sughayer¹,

Mansour²,

Nuirat³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Background Seroprevalence studies of SARS-CoV-2 antibodies are useful in assessing the epidemiological status in the community and the degree of spread. Objective To study the seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors in Jordan, at various points of time as the pandemic evolves in the community. Methods A total of 1374 blood donor were tested for the SARS-CoV-2 total immunoglobulin antibodies in 3 groups. The first and second group: 746 and 348 individuals were tested in June and September-2020 respectively. The 3 rd group of 292 were tested in February-2021. We utilized a qualitative assay (specificity: 99.8%, sensitivity: 100%). Results The first 2 groups (January-September, 2020) when the number of confirmed Covid-19 cases were several hundred-3000 showed a seroprevalence rate of 0% (95% CI 0.00%-0.51%). The 3 rd group (early February 2021), when the number reported confirmed case has reached 100 folds that of September 2020, revealed a seroprevalence of 27.4% (95% CI 22.5%-32.9%). Conclusions a dramatic rise in seroprevalence of SARS-CoV-2 antibodies was seen among healthy blood donors in Jordan in parallel with wide-spread intracommunity transmission of the disease. This information is useful to assess the degree of herd immunity and provides for better understanding of the pandemic.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic

Sughayer¹,

Mansour²,

Nuirat³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Those population-based seroprevalence studies varied in the targeted populations tested and the recruitment strategies used which may explain some of the variation. Among the populations tested are healthy blood donors (Sughayer et al, 2020, Slot et al, 2020, Daniel J. Nesbitt et al, 2021, Gallian et al, 2020, Olariu et al, 2021, Younas et al, 2020, Banjar et al, 2021, Uyoga et al, 2021, Busch and Stone, 2021, Martinez-Acuña et al, 2020, Saeed et al, 2021, Slot et al, 2020, Fiore et al, 2021. Again the seroprevalence among healthy blood donors and other population groups studied varied according to the community tested and the time of testing in terms of the pandemic evolution (Lai et al, 2020, Rostami et al, 2020 In this longitudinal study we aimed to estimate the seroprevalence of Covid-19 among healthy blood donors in Jordan at different points in time to assess the degree of community spread and herd immunity and to further understand the evolution of the pandemic.…”

Section: Introductionmentioning

confidence: 99%

Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic

Sughayer

Mansour

Nuirat

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The coronavirus disease 2019 (COVID-19) pandemic has resulted in more than 106 million cases of confirmed infection and more than 2.3 million deaths worldwide as of February 11th 2021. Seroprevalence studies are extremely useful in studying and assessing the epidemiological status in the community and the degree of spread. They help decision makers in implementing or relaxing mitigating measures to contain the disease in addition to other benefits. Objective: To study the seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors in Jordan, at various points of time as the pandemic evolves in the community. Methods: A total of 1374 blood donor were tested for the SARS-CoV-2 antibodies in 3 groups. The first group of 746 and the second of 348 individuals were tested in June and September of 2020 respectively. The 3rd group of 292 were tested in early February of 2021. We utilized a qualitative assay that uses Electrochemiluminescence method (ECLIA) that has a specificity and sensitivity of 99.8% and 100% respectively. Results: The first 2 groups representing the months of January to September of 2020, where the number of confirmed Covid-19 cases were several hundred to 3000 showed a seroprevalence rate of 0% (95% CI 0.00%, 0.51%). The 3rd group representing late January and early February 2021 when the number of reported confirmed case has reached 100 folds the numbers of September 2020, showed a seroprevalence of 27.4% (95% CI 22.5% and 32.9%). Conclusions: a dramatic rise in seroprevalence of SARS-CoV-2 antibodies was seen among healthy blood donors in Jordan in parallel with wide-spread intracommunity transmission of the disease. This information is useful to assess the degree of herd immunity and provides for better understanding of the pandemic.

show abstract

Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening”

Jin

Nesbitt

Yang

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic and local, regional and national public health policies designed to limit the spread of the epidemic as well as reopen cities and states, are best informed by reproducible, high throughput, and statically credible antibody (Ab) assays. To date, a myriad of Ab tests, both available and authorized for emergency use by the FDA, has led to confusion rather than insight per se. The present study reports the results of a rapid, point-in-time 1,000-person cohort study using serial blood donors in the New York City metropolitan area (NYC) using multiple serological tests, including enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). These were then tested and associated with assays for neutralizing Ab (NAb). Of the 1,000 NYC blood donor samples in late June and early July 2020, 12.1% and 10.9% were seropositive using the Ortho Total Ig and the Abbott IgG HTSA assays, respectively. These serological assays correlated with neutralization activity specific to SARS-CoV-2. The data reported herein suggest that seroconversion in this population occurred in approximately 1 in 8 blood donors from the beginning of the pandemic in NYC (considered March 1, 2020). These findings deviate with an earlier seroprevalence study in NYC showing 13.7% positivity. Collectively however, these data demonstrate that a low number of individuals have serologic evidence of infection during this first wave and suggest that the notion of herd immunity at rates of ~60% or higher are not near. Furthermore, the data presented herein show that the nature of the Ab-based immunity is not invariably associated with the development of NAb. While the blood donor population may not mimic precisely the NYC population as a whole, rapid assessment of seroprevalence in this cohort and serial reassessment could aid public health decision making.

show abstract

Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined Using Multiple Serological Assay Formats

Cited by 5 publications

References 17 publications

Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic

Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic

Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic

Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening”

Contact Info

Product

Resources

About